About Synedgen


Creating breakthrough therapeutics with glycomics

Synedgen is a pioneering biotechnology company using the science of glycomics to discover and develop polysaccharide-based drugs that enhance and mimic the innate immune system.

New class of polysaccharide-based drugs

This new class of drugs targets the complex interactions at the cell surface and mucosal interface. The mucosal surface provides the body’s natural barrier to infection and damage from outside contaminants and pathogens. Our pipeline shows potential to change disease progression in cystic fibrosis and other diseases, and improve quality of life for patients with diseases of the GI tract and pulmonary tree.

Our Glycomics Technology Platform enables us to design drugs with the ability to suppress inflammation, reduce infection and improve healing at these surfaces. We leverage this unique, proprietary technology engine to create new molecular entities that control the desired cellular response and direct activity at the source of the selected disease.

Creative solutions to difficult chemistry problems and unmet medical needs

Synedgen takes a unique scientific and applied clinical approach. Our technology simplifies the process to discover, develop and manufacture modified polysaccharides designed for therapeutic impact. We apply our platform strategically to address medical needs that cannot be met by other technologies, and translate these innovations into effective treatments.

Through our highly specialized, robust and predictive technology engine, we solve difficult chemistry problems previously inaccessible to traditional approaches. We have identified chemical properties required to ultra-purify polysaccharide molecules and designed chemical modifications to make the drugs soluble, active and targeted in the human body.

Our chemistry advantage produces a scientifically validated pipeline of drugs able to:

  • Mimic the body’s innate immune response to reduce inflammation and improve healing.
  • Protect mucosal surfaces from damage and microbial imbalance.
  • Control mucosal inflammation after damage and restore homeostasis.
  • Reduce the ability of bacteria to bind and invade tissues.
  • Restore the native environment to support the normal microbiome.

Intellectual Property

Synedgen has a broad US and international patent estate. The IP portfolio covers the overall platform as as well as use and compositions of matter for the specific products under development.